博瑞医药：待完成国内III期临床研究，并经国家药监局审评、审批通过后方可在国内生产上市

Core Viewpoint - The company BoRui Pharmaceutical (688166.SH) has announced that the Phase III clinical trials for its BGM0504 injection, targeting type 2 diabetes and weight loss, have completed patient enrollment and are currently in the dosing and follow-up stages, progressing as planned [1] Group 1 - The Phase III clinical trials for BGM0504 have completed all patient enrollments [1] - The trials are currently in the dosing and follow-up phases [1] - The company plans to complete the domestic Phase III clinical research and seek approval from the National Medical Products Administration before the product can be manufactured and marketed in China [1]